Is an antioxidative capacity of HI-6 oxime a key factor to improve the therapy with irinotecan? (CROSBI ID 544520)
Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Suzana Berend, Ana Lucić Vrdoljak, Božica Radić, Jasenka Piljac-Žegarac, Marin Mladinić, Davor Želježić, Nevenka Kopjar
engleski
Is an antioxidative capacity of HI-6 oxime a key factor to improve the therapy with irinotecan?
New and improved therapy modalities currently employed in the management of malignant diseases significantly contribute to the overall survival rate in cancer patients. Therefore, some compounds although not primarily designed as supportive drugs in chemotherapy, are promising candidates for possible clinical use. Our in vitro and in vivo experiments have demonstrated that HI-6 could “ protect” cholinesterases against the irinotecan, one of frequently used antineoplastic drugs, and in that way a part of cholinergic symptoms might be reduced. Interestingly, certain antioxidants may counteract the effects of chemotherapy-induced oxidative stress on the cell cycle and enhance the cytotoxicity of antineoplastic agents. So with the purpose to investigate the levels of oxidative stress and DNA damage (lipid peroxidation, the alkaline comet assay and micronucleus assay) related to treatments with irinotecan and HI-6 given alone or in combination we also focused on the assessment of possible antioxidative capacity of HI-6. In view of the DPPH assay results, HI-6 shows moderate radical scavenging at the tested concentration. Administration of HI-6 alone or with irinotecan diminished the levels of TBARS in rat plasma. Confirmatory results regarding HI-6 efficacy were also obtained by the alkaline comet and micronucleus assay. When given alone, it mostly did not induce significant disturbances in the level of primary DNA damage in somatic cells of treated rats and did not significantly induce the formation of micronuclei. Results obtained in the present study seems to be a proper argument to consider HI-6 as beneficial substance during chemotherapy.
HI-6; irinotecan; antioxidative capacity
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
S151-x.
2008.
nije evidentirano
objavljeno
Podaci o matičnoj publikaciji
Toxicology letters
Tsatsakis, Aristidis M., Liesivuori, Jyrki
0378-4274
Podaci o skupu
45th Congress of the European Societies of Toxicology
poster
05.10.2008-08.10.2008
Rodos, Grčka